Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTC2162
- Development stage
- Preclinical
- Lead developer
- Korea Institute of Science and Technology
- Modality
- Small Molecules
01
Overview
DTC2162 is a novel, highly potent, and selective small-molecule inhibitor of 4R tau aggregation developed by the Korea Institute of Science and Technology (KIST). It is being investigated for the treatment of tauopathies, specifically progressive supranuclear palsy (PSP) and Alzheimer's disease (AD). DTC2162 acts as a reversible covalent inhibitor of disulfide-dependent tau oligomerization, thereby preventing the formation of toxic tau oligomers and protecting against neuronal cell death. In preclinical models of tauopathy (P301L Tau-BiFC transgenic mice), DTC2162 has demonstrated significant efficacy in reducing tau pathology and restoring cognitive and motor functions.
02
Targets
MAPT (Microtubule-associated protein tau)
Beyond the preview
Go deeper on DTC2162.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTC2162.